Kornimate/medical-research-clean huggingface dataset:
origins and impact of eds in connective tissues and skin

Conditions: Ehlers-Danlos Syndrome

Summary: ehlers-danlos syndrome (eds) is an inherited disease of collagen, found in connective tissues, such as skin. eds patients suffer from joint and skin problems (skin hyperextensibility, joint hypermobility) along with a large range of other disorders, including, delayed wound healing with atrophic scarring, easy bruising, tissue fragility, gastrointestinal and gum problems. there are many different types of eds, with different mechanisms of action, and not all of these are well understood. this study will used advanced microscopy techniques called atomic force microscopy (afm) and scanning electron microscopy (sem) to analyse the changes in collagen as a result of eds, compared to normal collagen. these changes will be viewed at the micron and nanoscale level (between 1,000 to 100,000 x magnification), and will focus on the differences in collagen construction through a process called cross-linking. these changes could potentially help clinicians understand the root cause of eds symptoms, and provide a deeper knowledge of cross-linking disorders in collagen. increasing our knowledge of how collagen is affected in eds patients, may lead to improved treatment options for patients.


Eligibility criteria:
inclusion criteria: * adult (18+) patients requiring elective surgery as part of their treatment plan who fulfil the brighton criteria for joint hypermobility syndrome (jhs)/eds hypermobility type with significant joint hypermobility (beighton score of 6 and above) and /or have evidence of significant connective tissue weakness, or rectal/vaginal prolapse exclusion criteria: * patients with insufficient ability in english to give informed consent, if a translator is not present. * patients with severe developmental disorders, precluding their consent for research

Keywords: hypermobility collagen joint hyperflexation
use of a deskcycle to reduce sedentary behavior during the workday

Conditions: Chronic Disease; Reduction, Weight

Summary: the purpose of this research was to evaluate the effectiveness of a deskcycle intervention in reducing sedentary behavior by increasing the time spent participating in light to moderate physical activity in a randomly selected group of desk job employees at kent state university main campus. the study also assessed the feasibility of using the deskcycle in the working environment, as well as the effect on weight and mood. the primary outcome of interest was the 'mean minutes of light to moderate physical activity'. secondary outcomes include weight, mood score, and feasibility of using the deskcycle. the study was a randomized controlled trial (rct) with a cross-over design where differences between the intervention and control group were evaluated over an eight-week period, after which there was a switch and the deskcycles were given to the control group to use for the eight-week period that followed. the allocation during the first eight-week period intervention will be done through random process.


Eligibility criteria:
inclusion criteria: * females 18 years and above * full-time kent state university administrative employees at the kent main campus * sedentary for 75% of their workday * height under 5'10" * desk height of at least 27" exclusion criteria: * any uncontrolled cardiovascular diseases * back, knee or other joint pains
bradycardia following intraoperative administration of dexmedetomidine

Conditions: Tonsillectomy; Adenotonsillectomy

Summary: this is a retrospective chart review to evaluate the postoperative course of all pediatric patients admitted to the hospital following adenotonsillectomy over the past 24 months to evaluate the incidence of bradycardia in children who received dexmedetomidine intraoperatively and identify confounding factors which may be precipitating the bradycardia or potentiating the negative chronotropic effects of dexmedetomidine.


Eligibility criteria:
inclusion criteria: * patients undergoing adenontonsillectomy or tonsillectomy during 2011 and 2012. exclusion criteria: * none.
comparison of low and intermediate dose low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy

Conditions: Deep Venous Thrombosis; Pulmonary Embolism

Summary: this is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (lmwh) in pregnant patients with a history of previous venous thromboembolism (vte). both doses are recommended doses in the 2012 guidelines of the american college of chest physicians (accp), but it is not known which dose is more efficacious in preventing recurrent venous thromboembolism in pregnancy. patients enter the study and will be randomized as soon as a home test confirms pregnancy. lmwh will be administered until 6 weeks postpartum. follow-up will continue until 3 months postpartum. patients will be recruited by their treating physician, either an obstetrician or internist.


Eligibility criteria:
inclusion criteria: * age: 18 years or older, and; * pregnancy confirmed by urinary pregnancy test, and; * gestational age \< 14 weeks, and; * previous objectively confirmed vte, either unprovoked, in the presence of use of oral contraceptives or estrogen/progestagen use, or related to pregnancy or the postpartum period, or minor risk factors (e.g. long distance travel, minor trauma). exclusion criteria: * previous vte related to a major provoking risk factor (e.g. surgery, major trauma or plaster cast immobilisation in the 3 months prior to vte) as the sole risk factor, or; * indication for treatment with therapeutic dose anticoagulant therapy (e.g. treatment of acute vte; permanent use of therapeutic anticoagulants outside of pregnancy), or; * inability to provide informed consent, or; * any contraindication listed in the local labelling of lmwh.

Keywords: low-molecular-weight heparin pregnancy venous thrombosis
impact of early cognitive rehabilitation on functional outcomes following moderate traumatic brain injury

Conditions: TBI (Traumatic Brain Injury)

Summary: purpose of the study: this study aims to detect the impact of early cognitive rehabilitation on functional outcomes with patients following moderate traumatic brain injury.

intensive care unit (icu) hospitalization saves lives but often costs icu survivors, who often experience cognitive impairment and physical and functional disabilities. early physical rehabilitation improves chances of regaining pre-hospital functional status, but early cognitive rehabilitation for these patients remains unexplored traumatic brain injury occurs from violent blows or objects, causing physical and psychological effects. signs may appear immediately or days later, affecting the brain's function and functioning . traumatic brain injury (tbi) impacts health and quality of life, with unpredictable prognosis. exercise is crucial for neuroplasticity and brain rewiring.the glasgow coma scale, published in 1974, measures impaired consciousness in acute medical and trauma patients using eye-opening, motor, and verbal responses. it provides a clear, communicable picture of a patient's state. the rancho los amigos scale (rlas) is a medical assessment tool for individuals recovering from closed head injuries, including traumatic brain injuries. it evaluates cognitive and behavioral presentations as they emerge from coma, comparing patients' state of consciousness and reliance on assistance . the functional independence measure (fim) is an 18-item assessment tool for evaluating patients' functional status in rehabilitation after stroke, traumatic brain injury, spinal cord injury, or cancer. it evaluates self-care, continence, mobility, transfers, communication, and cognition, with each item rated 1-7 .

Eligibility criteria:
inclusion criteria: 1. both genders. 2. moderate traumatic brain injury patients will be included with gcs score 9-12. 3. patients' age 18 years old and more . 4. all patients must be medically stable post trauma. exclusion criteria: 1. children under 18 years old . 2. previous cerebral infarction and intracranial space-occupying lesions. 3. patients with cancer and major underlying illnesses. 4. patients with diffuse axonal damage. 5. incomplete clinical and imaging data 6. patient with other neurological deficits or orthopedic abnormalities that causing disability. 7. patients with serious psychiatric pathology or mentally. -

Keywords: cognition / tbi/
percutaneous vertebroplasty: prophylactic treatment of adjacent vertebra

Conditions: Osteoporosis; Vertebral Fracture

Summary: percutaneous vertebroplasty is a treatment for painful osteoporotic compression fractures. multiple reports have shown as high as 20 % refracturerates in vertebrae adjacent to those that have been treated with percutaneous vertebroplasty. the purpose of the study is to determine if prophylactic vertebroplasty of unfractured vertebrae adjacent to the treated fractured vertebrae can reduce the rates of refracture in adjacent vertebrae.


Eligibility criteria:
inclusion criteria: * ct and mri proven non healed painful osteoporotic compression fracture in the thoracic and lumbar spine. exclusion criteria: * infection * high grade spinal stenosis * contraindications to mri * dementia

Keywords: osteoporosis vertebroplasty prophylactic vertebrae fracture
post-market clinical investigation of the iotasoft insertion system

Conditions: Hearing Loss, Cochlear; Cochlear Implantation; Hearing Loss, Sensorineural

Summary: the purpose of the proposed study is to evaluate the continued safety of the iotasoft insertion system when used by a surgeon to assist with inserting a ci electrode array in one ear per subject

available iotasoft insertion system when used per intended use for insertion of a cochlear implant electrode array in subjects 12 years and older. the purpose of the study is to collect additional safety data in retrospective and prospective subjects. the primary object of the study is to demonstrate post-market safe use of the commercially available iotasoft insertion system. the secondary objective of the study is to define procedural characteristics including device deficiencies, electrode array insertion speed, rate of tip fold-over, and objective measures of cochlear implant functionality to demonstrate effective use of the commercially available iotasoft insertion system.

Eligibility criteria:
inclusion criteria: 1. candidates with sensorineural hearing loss who received or will receive unilateral or bilateral cochlear implantation according to indications for use with fda approved cochlear implant devices, as listed below: 1. advanced bionics hifocus slimj 2. cochlear slim straight 3. med-el flex 24 and 28 2. age 12 years or older at the time of ci surgery. 3. willingness to participate in the study and able to comply with the follow-up visit requirements. exclusion criteria: 1. prior cochlear implantation in the ear to be implanted. 2. ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array or present an increased risk of aberrant insertion. 3. craniofacial abnormality, temporal squamosal skull thickness less than 3mm, major cochlear lesions (e.g., fibrosis, fracture, or ossification), or cochlear malformations. 4. deafness due to lesions of the acoustic nerve or central auditory pathway. 5. diagnosis of auditory neuropathy. 6. active middle-ear infection or tympanic membrane perforation in the presence of active middle ear disease. 7. absence of cochlear development. 8. additional medical concerns that would prevent participation in evaluations as determined by the investigator. 9. unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the procedure and investigational device. 10. non-native english speakers who are unable to read, understand and/or speak english for completion of required procedures 11. planned or current participation in a clinical study of an investigational device or drug. 12. must not fit the definition of a vulnerable subjects, as per fda regulations 21 cfr parts 50 and 56

Keywords: cochlear implantation sensorineural hearing loss
cognitive remediation in forensic mental health care

Conditions: Psychotic Disorders; ADHD; TBI (Traumatic Brain Injury); Aggression; Substance Use Disorders; Violence; Cognitive Dysfunction; Anxiety; Depression; Schizophrenia; Offenders; Antisocial

Summary: forensic patients often display cognitive deficits, particularly in the domain of executive functions, that represent a challenge to forensic rehabilitation. one empirically-validated method to train executive functions is cognitive remediation, which consists of cognitive exercises combined with coaching. this trial investigates whether cognitive remediation can improve cognitive, functional, and clinical outcomes in forensic inpatients.

forensic patients often display deficits in executive functions, namely difficulties in planning, strategic thinking, problem-solving, and inhibiting inappropriate behavior. such deficits are transdiagnostic and often underlie behavioral incidents, undermine reintegration into the community, and increase recidivism risk. despite this, forensic programs usually do not include executive function training. one approach to train executive functions is cognitive remediation, which consists of behavioral exercises engaging cognitive skills, supported by coaching. in various mental health conditions, cognitive remediation has been repeatedly associated with improvements in cognitive, functional, and clinical outcomes, with small-to-moderate effect sizes. thus, it should be clarified whether this approach can lead to similar improvements in forensic populations. in the present trial, we will investigate whether 12 hours over 6 weeks of computerised cognitive remediation administered using tele-health can improve executive functions relative to an active control condition in a sample of 30 forensic inpatients (aim 1). we will further examine the effect of cognitive remediation (vs. active control) on other variables that are critical for forensic rehabilitation, namely oppositional behaviour, functional capacity, and mental health symptoms (aim 2). lastly, we will explore whether any effects persist 12 weeks following cognitive remediation (aim 3). cognitive remediation is an evidence-based inexpensive training method that could be integrated into forensic healthcare practice. in the long term, the expected cognitive, functional, and clinical improvements associated with cognitive remediation have the potential to result in shorter hospitalisations and reduced recidivism rates.

Eligibility criteria:
inclusion criteria: i1. age 18 - 55; i2. ability to read and speak in fluent english; i3. current status as inpatient on the forensic treatment unit. exclusion criteria: e1. intellectual disability; e2. tbi with loss of consciousness followed by known severe neurological sequelae requiring hospitalisation and rehabilitation.

Keywords: cognitive remediation cognitive training cognitive enhancement cognitive rehabilitation neuropsychological rehabilitation executive function forensic mental health forensic psychology forensic neuropsychology forensic neuroscience forensic rehabilitation cognition executive functioning
effect of vitis vinifera extract on oxidative stress, inflamatory biomarkers and hormones in high trained subjects

Conditions: Athletic Injuries

Summary: there is evidence that intense physical activity has a potential effect on thrombotic events due to catecholamine release. the hormones leptin and adiponectin have been used as markers of cardiovascular risk, but they are few and contradictory studies that relate physical training intensity and duration of high plasma concentrations of these hormones. the use of antioxidants, such as proanthocyanidins present in grapes, may help in reducing the undesirable effects of intense training.

fifty four brazilian healthy military without hyperglycemia, diabetes mellitus and endocrine disease were enrolled in this study. all subjects were high physically military trained. the ethical committee of the universidade do estado do rio de janeiro in brazil (coep008/2011) approved the study protocol. informed consent was obtained from each subject after explanation of purpose and risks of all procedures used.

Eligibility criteria:
inclusion criteria: * healthy physically active men exclusion criteria: * diabetes, hypertension, obesity subjects, drug use

Keywords: athletes, polyphenols, nutrition, oxidative stress
tislelizumab with fruquintinib, metronidazole, in mismatch repair-proficient or microsatellite stability, advanced colorectal cancer: a multicenter, single arm, clinical trial

Conditions: Colorectal Cancer

Summary: the aim of this study is to evaluate the efficacy and safety of tislelizumab with fruquintinib, metronidazole treatment in mss/msi-l advanced colorectal cancer patients with high abundance of fusobacterium nucleatum in a single arm phase ii clinical.


Eligibility criteria:
inclusion criteria: 1. no gender limit, age ≥ 18 years old and ≤ 80 years old; 2. colorectal cancer (ajcc stage iv) diagnosed by histological or cytological biopsy as metastatic or unresectable, with immunohistochemical or genetic testing indicating mss or msh-l type; 3. treatment requires third line or above, has previously received standard first and second line treatment, and the disease has progressed after treatment; 4. before accepting tirelizumab, qpcr should be used to detect the fn deltact value ≥ -22.24 in fecal samples; 5. ecog score: 0-1 points; 6. baseline blood routine and biochemical indicators meet the following criteria (no blood transfusion or use of colony stimulating factors 2 weeks prior to screening) blood routine: hemoglobin ≥ 90g/l, absolute neutrophil count (anc) ≥ 1.5 × 109/l, platelet ≥ 100 × 109/l liver function: alt and ast ≤ 2.5 x uln, serum total bilirubin ≤ 1.5 x uln (if there is liver metastasis, alt and ast ≤ 5 x uln, serum total bilirubin ≤ 3 x uln), serum albumin ≥ 30g/l renal function: serum creatinine ≤ 1.5 x upper limit of normal (uln), or creatinine clearance rate ≥ 50 ml/min (calculated according to cockcroft gault formula). 7. those who voluntarily participate in the trial and sign an informed consent form. exclusion criteria: 1. pregnant or lactating women; 2. chronic intestinal diseases (such as crohn's disease, ulcerative colitis, etc.), infectious intestinal diseases during the screening period, and intestinal obstruction during the screening period; 3. subjects with poor control of hypertension (systolic blood pressure\>150 mmhg and/or diastolic blood pressure\>100 mmhg) and a history of hypertensive crisis or hypertensive brain disease; 4. severe liver and kidney function or heart dysfunction; 5. patients who use antibiotics for more than 5 days within one month prior to immunotherapy; 6. patients with known brain or meningeal metastases, regardless of whether they have received treatment, are not eligible for inclusion in this trial. 7. individuals with contraindications to the use of metronidazole medication; 8. those who are unwilling to participate in the trial or sign informed consent forms; 9. the researchers believe that there are any situations that are not suitable for selection.
long-term safety study of inhaled insulin (cp-464,005, inhaler) in japanese patients with type1 or type2 diabetes

Conditions: Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1

Summary: assess the safety and toleration of cp-464,005 and inhaler following 1-year (52 week) administration to type 1 and type 2 diabetes patients (non-smokers)

pfizer announced in october 2007 that it would stop marketing cp-464,005. at that time recruitment for study, a2171105 was placed on hold. nektar, the company from which pfizer licensed cp-464,005, announced on april 9, 2008 that it had stopped its search for a new marketing partner. as a result, study a2171105 was terminated on april 10, 2008. neither safety nor efficacy reasons were the cause of the study termination.

Eligibility criteria:
inclusion criteria: * patients who have been diagnosed with type 1 or type 2 diabetes for at least 1 year, based on the diagnostic criteria for diabetes. exclusion criteria: * patients who have smoked during the 6 months prior to screening (smoking shall be prohibited during the term of this study, as well) * patients exhibiting pulmonary function test (spirometry) abnormalities (fvc or fev1 \< 70% of predicted) ) at week -4.

Keywords: diabetes mellitus
cryospray ablation(tm)to determine safety and feasibility in radiation induced proctitis

Conditions: Radiation Proctitis; Radiation Induced Proctitis

Summary: the purpose of this study is to evaluate the safety, feasibility, tissue response, and subject side effects of liquid nitrogen sprayed through a catheter (cryospray ablationtm, "csa" or "cryospray therapy") via endoscope in subjects with radiation induced proctitis.

the proposed study is a single center, ten patient pilot study to evaluate the safety and feasibility of sprayed liquid nitrogen through a catheter via endoscope in subjects with radiation proctitis. there will be two groups. subjects in group 1 will receive a cryospray applied to healthy tissue for 10 seconds. the cryospray will be repeated four (4) times in sequential fashion for a total of 40 seconds of cryospray therapy. subjects in group 2 will receive a cryospray applied to healthy tissue for 20 seconds. the cryospray will be repeated two (2) times in sequential fashion for a total of 40 seconds of cryospray therapy.

Eligibility criteria:
inclusion criteria: * age 18 years of age * have radiation induced proctitis exclusion criteria: * pregnant or nursing * planning to become pregnant during the course of the study * planning to sire a child while enrolled in the study * known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines. subject has prior or concurrent ablation therapy including, but not limited to, photodynamic therapy, multipolar electro coagulation, argon plasma coagulation, laser treatment, radio frequency, etc * refusal or inability to give consent. * concurrent chemotherapy. * medical contraindication or potential problem that would preclude study participation * concurrent participation in other experimental studies * uncontrolled coagulopathy or bleeding diathesis * portal hypertension due to cirrhosis manifest by esophageal, gastric or rectal varices

Keywords: radiation proctitis radiation induced proctitis